Document is current
Any future updates will be listed below
-
Authors
Esaki, Nobutoshi
Sakoda, Tomoka
Ando, Ryota
Miyai, Yuki
Iida, Tadashi
Mizutani, Yasuyuki https://orcid.org/0000-0002-4363-3161
Yoshida, Mirai
Hara, Yuki
Matsuyama, Makoto https://orcid.org/0000-0003-2606-059X
Kobayashi, Tomoe
Shiraki, Yukihiro https://orcid.org/0000-0003-3666-0556
Mii, Shinji https://orcid.org/0000-0001-8266-3235
Ichikawa, Jiro https://orcid.org/0000-0002-9850-6047
Kawasaki, Tomonori
Manabe, Shino https://orcid.org/0000-0002-2763-1414
Sakai, Tomohisa
Nishida, Yoshihiro https://orcid.org/0000-0002-7511-6388
Takahashi, Masahide
Enomoto, Atsushi https://orcid.org/0000-0002-9206-6116
-
Funding
Funding for this research was provided by:
Aichi Cancer Research Foundation
- License Information
-
More Information
Article History
Received: 31 March 2025
Revised: 19 September 2025
Accepted: 9 October 2025
First Online: 21 October 2025
Competing interests
: A.E. received a research grant from BFACT Co., Ltd.; N.E., M.M., M.T., and A.E. are founders of BFACT Co., Ltd.; N.E. is a representative of BFACT Co., Ltd.; Nagoya University licensed a patent relating to anti-Meflin antibody-drug conjugates to BFACT Co., Ltd. in 2021.
